Systemic and intrathecal effects of a novel series of phospholipase A 2 inhibitors on hyperalgesia and spinal prostaglandin E2 release

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 1, 2006, Pages 466-475

  Yaksh, Tony L ^a   Kokotos, George ^c   Svensson, Camilla I ^a   Stephens, Daren ^b   Kokotos, Christoforos G ^c   Fitzsimmons, Bethany ^a   Hadjipavlou Litina, Dimitra ^d   Hua, Xiao Ying ^a   Dennis, Edward A ^b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2 OXOHEXADECANOYL)AMINO]BUTANOIC ACID; ANANDAMIDE; AX 006; AX 010; AX 048; AX 057; CANNABINOID RECEPTOR ANTAGONIST; CARRAGEENAN; ETHYL 4 [(2 OXOHEXADECANOYL)AMINO]BUTANOATE; METHYL 4 [(2 OXOHEXADECANOYL)AMINO]BUTANOATE; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; RECOMBINANT ENZYME; SR 141617A; TERT BUTYL 4 [(2 OXOHEXADECANOYL)AMINO]BUTANOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATHETER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERALGESIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CARRAGEENAN; CHEMISTRY, PHYSICAL; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GAMMA-AMINOBUTYRIC ACID; HEAT; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SPINAL; MALE; MICRODIALYSIS; OXIDATION-REDUCTION; PHOSPHOLIPASES A; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SPINAL CORD; SUBSTANCE P;

EID: 29244483379     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.091686     Document Type: Article

References (40)

1. Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4:461-485.
2. Burke JR, Davern LB, Stanley PL, Gregor KR, Banville J, Remillard R, Russell JW, Brassil PJ, Witmer MR, Johnson G, et al. (2001) BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J Pharmacol Exp Ther 298:376-385.
3. Dirig DM, Salami A, Rathbun ML, Ozaki GT, and Yaksh TL (1997) Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods 76:183-191.
4. Dole VP (1956) A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Investig 35:150-154.
5. Ebersberger A, Grubb BD, Willingale HL, Gardiner NJ, Nebe J, and Schaible HG (1999) The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord. Neuroscience 93:775-781.
6. Evans AR, Junger H, Southall MD, Nicol GD, Sorkin LS, Broome JT, Bailey TW, and Vasko MR (2000) Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J Pharmacol Exp Ther 293:912-920.
7. Ferreira SH (1972) Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol 240:200-203.
8. 2 synthase-1. J Biol Chem 279:24866-24872.
9. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, and Ueda H (2004) Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10:712-718.
10. Jaranowska A, Bussolino F, Sogos V, Arese M, Lauro GM, and Gremo F (1995) Platelet-activating factor production by human fetal microglia. Effect of lipopolysaccharides and tumor necrosis factor-alpha. Mol Chem Neuropathol 24:95-106.
11. Kokotos G, Kotsovolou S, Six DA, Constantinou-Kokotou V, Beltzner CC, and Dennis EA (2002) Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). J Med Chem 45:2891-2893.
12. Kokotos G, Six DA, Loukas V, Smith T, Constantinou-Kokotou V, Hadjipavlou-Litina D, Kotsovolou S, Chiou A, Beltzner CC, and Dennis EA (2004) Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells and in vivo. J Med Chem 47:3615-3628.
13. Kulmacz RJ and Lands WE (1983) Requirements for hydroperoxide by the cyclooxygenase and peroxidase activities of prostaglandin H synthase. Prostaglandins 25:531-540.
14. L'Hirondel M, Cheramy A, Artaud F, Godeheu G, and Glowinski J (1999) Contribution of endogenously formed arachidonic acid in the presynaptic facilitatory effects of NMDA and carbachol on dopamine release in the mouse striatum. Eur J Neurosci 11:1292-1300.
15. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
16. Lucas KK, Svensson CI, Hua XY, Yaksh TL, and Dennis EA (2005) Spinal phospholipase A(2) in inflammatory hyperalgesia: role of Group IVA cPLA(2). Br J Pharmacol 144:940-952.
17. Malmberg AB and Yaksh TL (1992) Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science (Wash DC) 257:1276-1279.
18. Malmberg AB and Yaksh TL (1995) Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J Neurosci 15:2768-2776.
19. Morita K, Morioka N, Abdin J, Kitayama S, Nakata Y, and Dohi T (2004) Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice. Pain 111:351-359.
20. Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Narumiya S, Muller U, and Zeilhofer HU (2005) Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Investig 115:673-679.
21. Rice AS, Farquhar-Smith WP, and Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66:243-256.
22. Richards DA, Bliss TV, and Richards CD (2003) Differential modulation of NMDA-induced calcium transients by arachidonic acid and nitric oxide in cultured hippocampal neurons. Eur J Neurosci 17:2323-2328.
23. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, and Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature (Lond) 410:471-475.
24. Sapirstein A and Bonventre JV (2000) Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim Biophys Acta 1488:139-148.
25. Seidel K, Hamza M, Ates M, and Guhring H (2003) Flurbiprofen inhibits capsaicin induced calcitonin gene related peptide release from rat spinal cord via an endocannabinoid dependent mechanism. Neurosci Lett 338:99-102.
26. Seung Lee W, Hong MP, Hoon Kim T, Kyoo Shin Y, Soo Lee C, Park M, and Song JH (2005) Effects of lysophosphatidic acid on sodium currents in rat dorsal root ganglion neurons. Brain Res 1035:100-104.
27. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, and Ferrara P (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65:627-635.
28. Southall MD, Michael RL, and Vasko MR (1998) Intrathecal NSAIDS attenuate inflammation-induced neuropeptide release from rat spinal cord slices. Pain 78:39-48.
29. Svensson CI, Fitzsimmons B, Azizi S, Powell HC, Hua XY, and Yaksh TL (2005a) Spinal p38beta isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J Neurochem 92:1508-1520.
30. Svensson CI, Lucas KK, Hua XY, Powell HC, Dennis EA, and Yaksh TL (2005b) Spinal phospholipase A(2) in inflammatory hyperalgesia: role of the small, secretory phospholipase A(2). Neuroscience 133:543-553.
31. Svensson CI and Yaksh TL (2002) The spinal phospholipase-cyclooxygenase- prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 42:553-555.
32. Swan PW and Tukker JJ (1997) Molecular determinants of recognition for the intestinal peptide carrier. J Pharm Sci 86:596-602.
33. Taiwo YO and Levine JD (1988) Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 8:1346-1349.
34. Turnbach ME and Randich A (2001) The effect of spinal and systemic administration of indomethacin on zymosan-induced edema, mechanical hyperalgesia and thermal hyperalgesia. J Pain 2:25-35.
35. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
36. Yaksh TL (1982) Central and peripheral mechanisms for the antianalgesic action of acetylsalicylic acid, in Acetylsalicylic Acid: New Uses for an Old Drug (Barnet JM, Hirsh J, and Mustard JF eds) pp 137-152, Raven Press, New York.
37. 2 is mediated by the inhibition of constitutive spinal COX-2 but not COX-1. J Neurosci 21:5847-5853.
38. Yaksh TL and Rudy TA (1976) Chronic catheterization of the spinal sub-arachnoid space. Physiol Behav 17:1031-1036.
39. Yamamoto T and Nozaki-Taguchi N (1996) Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor and NS-398, a COX-2 selective inhibitor. Brain Res 739:104-110.
40. Yeo JF, Ong WY, Ling SF, and Farooqui AA (2004) Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice. Pain 112:148-155.